Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02521766




Registration number
NCT02521766
Ethics application status
Date submitted
6/08/2015
Date registered
13/08/2015
Date last updated
14/05/2020

Titles & IDs
Public title
A Clinical Investigation of the ClarVista HARMONI™ Modular Intraocular Lens Implant Following Cataract Surgery
Scientific title
A Prospective, Multi-Center, Feasibility Trial of the ClarVista HARMONI™ Modular Intraocular Lens System for the Treatment of Aphakia Following Cataract Surgery
Secondary ID [1] 0 0
CP-00001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cataract 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Harmoni Modular Intraocular Lens
Treatment: Devices - Commercially Available Intraocular Lens
Treatment: Surgery - Optic exchange

Experimental: All HMIOL Cohort - HMIOL implantation with or without optic exchange

Experimental: Cohort 1 - HMIOL implantation with no optic exchange

Experimental: Cohort 2 - HMIOL implantation with optic exchange

Other: Fellow Eye - IOL implantation per standard of care


Treatment: Devices: Harmoni Modular Intraocular Lens
Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag

Treatment: Devices: Commercially Available Intraocular Lens
IOL per investigator's standard of care

Treatment: Surgery: Optic exchange
Removal of one optic and replacement with another for the purpose of improving refractive outcomes
Intervention code [1] 0 0
Treatment: Devices
Intervention code [2] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Eyes With Postoperative BCDVA 20/40 Snellen or Better by Study Visit - All HMIOL Cohort
Timepoint [1] 0 0
Month 1 postoperative, Month 3 postoperative
Primary outcome [2] 0 0
Percentage of Eyes With Postoperative BCDVA 20/40 Snellen or Better by Study Visit - Cohort 1
Timepoint [2] 0 0
Month 1 postoperative, Month 3 postoperative, Month 6 postoperative, Month 12 postoperative
Primary outcome [3] 0 0
Percentage of Eyes With Postoperative BCDVA 20/40 Snellen or Better by Study Visit - Cohort 2
Timepoint [3] 0 0
Month 1 postoperative, Month 3 postoperative, Week 1 post-optic exchange, Month 1 post-optic exchange, Month 3 post-optic exchange, Month 6 post-optic exchange, Month 12 post-optic exchange
Primary outcome [4] 0 0
Percentage of Eyes With Postoperative BCDVA 20/40 Snellen or Better by Study Visit - Fellow Eye
Timepoint [4] 0 0
Month 1 postoperative, Month 3 postoperative, Month 12 postoperative
Primary outcome [5] 0 0
Percentage of Eyes With Postoperative Manifest Refraction Spherical Equivalent (MRSE) Within Target by Study Visit - All HMIOL Cohort
Timepoint [5] 0 0
Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Primary outcome [6] 0 0
Percentage of Eyes With Postoperative Manifest Refraction Spherical Equivalent (MRSE) Within Target by Study Visit - Cohort 1
Timepoint [6] 0 0
Week 1 postoperative, Month 1 postoperative, Month 3 postoperative, Month 6 postoperative, Month 12 postoperative
Primary outcome [7] 0 0
Percentage of Eyes With Postoperative Manifest Refraction Spherical Equivalent (MRSE) Within Target by Study Visit - Cohort 2
Timepoint [7] 0 0
Week 1 postoperative, Month 1 postoperative, Month 3 postoperative, Week 1 post-optic exchange, Month 1 post-optic exchange, Month 3 post-optic exchange, Month 6 post-optic exchange, Month 12 post-optic exchange
Primary outcome [8] 0 0
Percentage of Eyes With Postoperative Manifest Refraction Spherical Equivalent (MRSE) Within Target by Study Visit - Fellow Eye
Timepoint [8] 0 0
Month 1 postoperative, Month 3 postoperative, Month 12 postoperative
Primary outcome [9] 0 0
Mean BCDVA (Letters Read) by Study Visit - All HMIOL Cohort
Timepoint [9] 0 0
Day -90 to Day -1 preoperative, Month 1 postoperative, Month 3 postoperative
Primary outcome [10] 0 0
Mean BCDVA (Letters Read) by Study Visit - Cohort 1
Timepoint [10] 0 0
Day -90 to -1 preoperative, Month 1 postoperative, Month 3 postoperative, Month 6 postoperative, Month 12 postoperative
Primary outcome [11] 0 0
Mean BCDVA (Letters Read) by Study Visit - Cohort 2
Timepoint [11] 0 0
Day -90 to -1 preoperative, Month 1 postoperative, Month 3 postoperative, Week 1 post-optic exchange, Month 1 post-optic exchange, Month 3 post-optic exchange, Month 6 post-optic exchange, Month 12 post-optic exchange
Primary outcome [12] 0 0
Mean BCDVA (Letters Read) by Study Visit - Fellow Eye
Timepoint [12] 0 0
Day -90 to -1 preoperative, Month 1 postoperative, Month 3 postoperative, Month 12 postoperative
Primary outcome [13] 0 0
Mean Uncorrected Distance Visual Acuity (UCDVA) (Letters Read) by Study Visit - All HMIOL Cohort
Timepoint [13] 0 0
Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative
Primary outcome [14] 0 0
Mean Uncorrected Distance Visual Acuity (UCDVA) (Letters Read) by Study Visit - Cohort 1
Timepoint [14] 0 0
Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative, Month 6 postoperative, Month 12 postoperative
Primary outcome [15] 0 0
Mean Uncorrected Distance Visual Acuity (UCDVA) (Letters Read) by Study Visit - Cohort 2
Timepoint [15] 0 0
Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative, Day 1 post-optic exchange, Week 1 post-optic exchange, Month 1 post-optic exchange, Month 3 post-optic exchange, Month 6 post-optic exchange, Month 12 post-optic exch
Primary outcome [16] 0 0
Mean Uncorrected Distance Visual Acuity (UCDVA) (Letters Read) by Study Visit - Fellow Eye
Timepoint [16] 0 0
Day 1 postoperative, Week 1 postoperative, Month 1 postoperative, Month 3 postoperative, Month 6 postoperative, Month 12 postoperative
Primary outcome [17] 0 0
Percentage of Eyes With UCDVA by Category (Snellen) for Each Post-optic Exchange Study Visit - Cohort 2
Timepoint [17] 0 0
Day 1 post-optic exchange, Week 1 post-optic exchange, Month 1 post-optic exchange, Month 3 post-optic exchange, Month 6 post-optic exchange, Month 12 post-optic exchange
Primary outcome [18] 0 0
Mesopic Best Corrected Distance Visual Acuity (mBCDVA) (With and Without Glare) (Letters Read) at Study Visit - All HMIOL Cohort
Timepoint [18] 0 0
Month 3 postoperative

Eligibility
Key inclusion criteria
* Must be able to understand and provide informed consent
* Must be willing and able to return for scheduled treatment and follow-up examinations for up to 15 month study duration
* Planned bilateral removal of visually significant bilateral cataracts
* Best-corrected distance visual acuity (BCDVA) projected to be better than 20/32 after IOL implantation in both eyes
* Preoperative bilateral BCDVA of 20/40 or worse
* Both eyes must have corneal astigmatism = 1.50 diopter (D)
* Women must be post-menopausal =1 year or surgically sterilized, or a pregnancy screen must be performed prior to the study and a reliable form of contraception, approved by the investigator, must be maintained during the study
* Dilated pupil size equal to or greater than 6 millimeters (mm) in primary study eye
* Other protocol-specified inclusion criteria may apply.
Minimum age
22 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participation in any other drug or device clinical trial within 30 days prior to enrolling in this study and/or during study participation
* History of any intraocular or corneal surgery in either eye (including refractive)
* History of any clinically significant retinal pathology or ocular diagnosis in either eye
* History of any ocular conditions which could affect the stability of the IOL
* Uncontrolled glaucoma in either eye
* Other protocol-specified exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Single group
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
26/10/2017
Sample size
Target
Accrual to date
Final
217
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Auckland
Country [2] 0 0
Philippines
State/province [2] 0 0
Manila

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
ClarVista Medical
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main objectives of this feasibility study were:

* To demonstrate the feasibility of HARMONI Modular Intraocular Lens (HMIOL) implantation and assembly in subjects undergoing cataract surgery (All HMIOL Cohort), and
* To demonstrate the feasibility of the HMIOL optic component exchange procedure (performed 3 months following primary cataract extraction) (Cohort 2).
Trial website
https://clinicaltrials.gov/study/NCT02521766
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sr. CDMA Project Lead, Surgical
Address 0 0
Alcon Research, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02521766